ATG9A and cardiac hypertrophy: Inhibition of miR‐34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.22 In Angiotensin II‐induced cardiac hypertrophy, miR‐34a inhibits ATG9A expression and autophagy activity.35 During heart failure, miR‐34a inhibition alleviates RBFox2 depletion‐induced heart dysfunction.36 Besides, miR‐34a regulates cardiomyocyte apoptosis.